Inspra

Eplerenone, the active ingredient in Inspra, is a mineralocorticoid receptor antagonist presented as an oral tablet for oral use. It is employed to manage high blood pressure and certain forms of heart failure, particularly in patients who benefit from aldosterone blockade.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inspra, a selective aldosterone receptor antagonist, is used in conditions where excess mineralocorticoid activity contributes to disease.

- Hypertension: lowers blood pressure by promoting sodium excretion and reducing fluid volume. - Heart failure (reduced ejection fraction): improves cardiac remodeling and decreases mortality. - Post‑myocardial infarction heart failure: reduces the risk of cardiovascular death and hospitalization.

Eplerenone may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Hyperkalaemia: elevated serum potassium levels. - Hyponatraemia: low sodium concentration. - Dizziness or light‑headedness. - Headache. - Fatigue. - Gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hyperkalaemia leading to cardiac arrhythmia. - Acute kidney injury. - Allergic reactions such as rash or angioedema. - Hepatic dysfunction. - Gynecomastia (rare). - Hormonal disturbances affecting menstrual cycles.

Before initiating Inspra, clinicians should assess renal function, electrolyte status, and concomitant medications that affect potassium.

- Renal impairment: adjust dose or avoid if severe. - Hyperkalaemia risk: monitor serum potassium regularly. - Concomitant potassium‑sparing diuretics: avoid combined use. - Pregnancy: use only if benefits outweigh risks. - Breastfeeding: consider potential exposure to infant. - Drug‑induced electrolyte shifts: correct abnormalities before starting. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Eplerenone interacts with several drug classes that influence potassium balance or renal clearance.

Major Interactions (Avoid): - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalaemia. - ACE inhibitors or ARBs: synergistic increase in potassium levels. - Cyclosporine: reduces eplerenone clearance, raising exposure.

Moderate Interactions (Monitor Closely): - NSAIDs: may impair renal function, affecting potassium handling. - Digoxin: increased risk of toxicity when hyperkalaemia occurs. - Lithium: altered lithium clearance, requiring level monitoring.